유전자 벡터 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Gene Vector Market size is expected to reach USD 7.74 Billion in 2034 from USD 2.45 Billion (2025) growing at a CAGR of 13.61% during 2026-2034.

The Global Gene Vector Market is experiencing strong growth due to the rapid advancement of gene therapy and biotechnology research. Gene vectors are essential tools used to deliver genetic material into cells for therapeutic purposes. With increasing research activities focused on treating genetic disorders, cancer, and rare diseases, the demand for efficient and safe gene delivery systems is rising. The growing number of clinical trials for gene-based therapies is also contributing significantly to market expansion.

Major growth drivers include technological advancements in viral and non-viral vector development, along with increased funding from governments and private investors. Pharmaceutical and biotechnology companies are heavily investing in gene therapy pipelines, which requires high-quality gene vectors. The rising prevalence of genetic diseases and the demand for personalized medicine are further supporting market growth. Regulatory approvals for new gene therapies are also creating new opportunities for vector manufacturers.

In the future, the market is expected to expand rapidly as more gene therapies move from clinical trials to commercialization. Innovations in vector engineering, improved safety profiles, and scalable manufacturing processes will play a key role in shaping the market. Collaborations between research institutions and biotech firms will accelerate product development. As gene therapy becomes more widely accepted, the gene vector market is set to experience long-term and transformative growth.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Vector Type

• Plasmid Dna
• Adenoviral
• Adeno-Associated Viral
• Retroviral
• Lentiviral
• Other Vector Types

By Application

• Gene Therapy
• Vaccinology
• Other Applications

By Diseases

• Oncology
• Genetic Disorders
• Infectious Diseases
• Other Diseases

By End-Use

• CDMOs
• Pharmaceutical And Biotechnology Companies
• Research Institutes
• CROs

COMPANIES PROFILED

• Cobra Biologics, Fuji film Diosynth Biotechnologies, Sirion Biotech, Merck KGaA, Thermo Fisher Scientific, Lonza, Oxford Biomedica, Novasep, Spark Therapeutics, Kaneka Eurogentec, Finvector Vision Therapies, Brammer Bio
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL GENE VECTOR MARKET: BY VECTOR TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Vector Type
• 4.2. Plasmid Dna Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Adenoviral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Adeno-Associated Viral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Retroviral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Lentiviral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.7. Other Vector Types Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL GENE VECTOR MARKET: BY APPLICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Application
• 5.2. Gene Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Vaccinology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Other Applications Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL GENE VECTOR MARKET: BY DISEASES 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Diseases
• 6.2. Oncology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Genetic Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Infectious Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Other Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL GENE VECTOR MARKET: BY END-USE 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast End-use
• 7.2. CDMOs Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Pharmaceutical And Biotechnology Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Research Institutes Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.5. CROs Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL GENE VECTOR MARKET: BY REGION 2022-2034(USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Vector Type
  • 8.2.2 By Application
  • 8.2.3 By Diseases
  • 8.2.4 By End-use
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Vector Type
  • 8.3.2 By Application
  • 8.3.3 By Diseases
  • 8.3.4 By End-use
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Vector Type
  • 8.4.2 By Application
  • 8.4.3 By Diseases
  • 8.4.4 By End-use
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Vector Type
  • 8.5.2 By Application
  • 8.5.3 By Diseases
  • 8.5.4 By End-use
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 South East Asia
  • 8.5.10 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Vector Type
  • 8.6.2 By Application
  • 8.6.3 By Diseases
  • 8.6.4 By End-use
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL GENE VECTOR INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Cobra Biologics
  • 10.2.2 Fuji Film Diosynth Biotechnologies
  • 10.2.3 Sirion Biotech
  • 10.2.4 Merck KGaA
  • 10.2.5 Thermo Fisher Scientific
  • 10.2.6 Lonza
  • 10.2.7 Oxford Biomedica
  • 10.2.8 Novasep
  • 10.2.9 Spark Therapeutics
  • 10.2.10 Kaneka Eurogentec
  • 10.2.11 Finvector Vision Therapies
  • 10.2.12 Brammer Bio